Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

PTC Therapeutics: Solid data from its oral product Risdiplam in spinal muscular atrophy

October 4, 2018 0

PTC Therapeutics’ (PTCT) product Risdiplam demonstrated safety and tolerability at all the doses used in the …

The FDA granted Paratek two important product approvals. One is for acne

October 3, 2018 0

The U.S. Food and Drug Administration (FDA) has approved Paratek Pharmaceuticals’ (PRTK) product Seysara™ (sarecycline) for inflammatory lesions of non-nodular …

Outperformance, Underperformance and Volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

October 1, 2018 0

Seattle Genetics (SGEN) and Takeda Pharmaceutical Limited (TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris …

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

September 27, 2018 0

The high risk of premature death from cardiovascular disease is believed to be caused by an …

AstraZeneca: Advancing and improving Stage III lung cancer treatments

September 26, 2018 0

Stage III (locally-advanced) NSCLC is commonly divided into three sub-categories: IIIA, IIIB and IIIC, defined by …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

The medical news of the year comes at the hands of Abott

September 24, 2018 0

While preparing The Week in Review issue from Prohost, our attention shifted towards historical news about …

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

September 21, 2018 0

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

September 20, 2018 0

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

September 20, 2018 0

Exelixis’ (EXEL) partner Ipsen Biopharmaceuticals Canada Inc. received approval of Cabometyx®(cabozantinib) tablets from Health Canada for adults with …

CRISPR Therapeutics’ new collaboration targeting Diabetes

September 19, 2018 0

CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases …

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver disease

September 18, 2018 2

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic …

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

September 17, 2018 0

Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune …

AcelRx Pharmaceuticals: A small currently highlighted firm

September 14, 2018 0

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX). The increased investors’ activity …

Gilead Sciences: In pursuit of cures for intractable diseases

September 13, 2018 0

Gilead Sciences (GILD) has news that we felt good about it for a company that saved …

CRISPR gene editing firms clear investors’ confusion

September 12, 2018 0

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific …

Amgen and AstraZeneca have in hand a very much needed Asthma drug

September 11, 2018 0

In the Week in Review posted yesterday on our website that is experiencing several attempts on …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Gilead and Galapagos have good news for patients with severely active Ankylosing Spondylitis

September 7, 2018 0

Gilead Sciences’ (GILD) and Galapagos’ (GLPG) product filgotinib – a highly selective JAK1 inhibitor has met …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd